Infectious Disease Diagnostic Market by Product (Instruments, Reagents, Software & Services), Technology (Biochemical Technology, Conventional Technology, Molecular Technology), Testing Type, Sample, Application, End User - Global Forecast 2024-2030

Infectious Disease Diagnostic Market by Product (Instruments, Reagents, Software & Services), Technology (Biochemical Technology, Conventional Technology, Molecular Technology), Testing Type, Sample, Application, End User - Global Forecast 2024-2030

The Infectious Disease Diagnostic Market size was estimated at USD 24.76 billion in 2023 and expected to reach USD 26.44 billion in 2024, at a CAGR 7.29% to reach USD 40.53 billion by 2030.

Infectious disease diagnostics products are designed to detect and identify pathogens that cause human infections. These diagnostics play a critical role in healthcare by facilitating the accurate and timely recognition of infectious agents, thus ensuring prompt and appropriate clinical management. The modalities for infectious disease diagnostics include culture techniques, molecular diagnostics, serology, antigen-based tests, and next-generation sequencing for guiding treatment decisions, monitoring disease outbreaks, and implementing infection control measures to prevent the spread of pathogens within communities and healthcare settings. In recent years, outbreaks of infectious diseases have resulted in an urgent need for reliable diagnostics. In addition, growth in healthcare spending and improvements in laboratory infrastructure globally contribute to the penetration of infectious disease diagnostic solutions. Moreover, government initiatives and regulatory approvals for innovative diagnostic solutions have expanded the availability of novel infectious disease diagnostic solutions. However, high costs associated with advanced diagnostic technologies could limit adoption in cost-sensitive regions. The lack of skilled professionals in emerging markets to operate sophisticated diagnostic equipment may restrict product penetration. Nevertheless, the integration of advanced technologies for enhanced data analysis and interpretation of complex diagnostic tests has enhanced the outputs of diagnostic tests. In addition, continuous development in diagnostic technologies, including rapid PCR systems and next-generation sequencing, drives the demand for infectious disease diagnostics products by offering quicker and more accurate results.

Regional Insights

The infectious disease diagnostic market in the Americas is observing rapid growth due to the increasing prevalence of infectious diseases, advanced diagnostic technologies, and growing awareness of early disease detection. The adoption of advanced technologies, well-established healthcare infrastructure, and the presence of the majority of vendors contribute to the infectious disease diagnostic market in the Americas. European Union's (EU) regulations and a sophisticated healthcare system largely influence Europe's market. EU countries invest heavily in research and innovation, exemplified by initiatives to foster the development of advanced diagnostics and resonate with proactive customer behavior toward disease prevention and management. The Middle East market is directed by significant healthcare spending and the adoption of high-tech diagnostic equipment, particularly in Gulf Cooperation Council (GCC) countries. The need for accessible and affordable diagnostics to combat prevalent infectious diseases such as HIV/AIDS, tuberculosis, and malaria has improved the need for infectious disease diagnosis products in Africa. The infectious disease diagnostic market in the Asia-Pacific is expanding rapidly due to its large population and increased healthcare expenditure. The government's focus on healthcare reform and the rise of domestic companies contribute to the growth of infectious disease diagnostics.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Infectious Disease Diagnostic Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Increasing global prevalence and periodic outbreaks of infectious diseases
Shift in focus towards decentralized point-of-care testing from centralized laboratories
Supportive government initiatives and investments toward infectious disease control and prevention

Market Restraints

Inadequate reimbursements and rising healthcare costs limiting the use of novel diagnostic techniques

Market Opportunities

Advancements in infectious disease diagnostics kits and solutions
Emergence of infectious disease diagnostics kits for homecare settings

Market Challenges

Accuracy issues and limited availability of skilled professionals

Market Segmentation Analysis

Product: Advancing applications of analytical instruments for infectious disease diagnostics
Testing Type: Emerging adoption of Point-of-Care (PoC) testing for convenience and emergency applications
Application: Increasing use of disease diagnosis kits to diagnose viral infections
End-User: Penetration of infectious disease diagnosis products in hospitals

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Infectious Disease Diagnostic Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Infectious Disease Diagnostic Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica, headquartered in Espoo, Finland, strategically expanded its capabilities in the in vitro diagnostics (IVD) sector with the successful acquisition of ViroStat LLC, a Maine-based pioneer in developing viral antibodies and antigens. This move bolsters Medix Biochemica's product offerings with ViroStat's high-quality antibodies targeting respiratory and gastrointestinal infections, sexually transmitted diseases, and food-borne pathogens.

Oxford Nanopore and bioMérieux to Enter into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics

Oxford Nanopore Technologies partnered with bioMérieux SA, a provider of in vitro diagnostics, to enhance global health outcomes by introducing nanopore sequencing into infectious disease diagnostics. This alliance promises a leap forward in patient care, with Oxford Nanopore providing cutting-edge, cost-effective sequencing solutions that could significantly streamline and improve pathogen detection in clinical settings.

Thermo Fisher Scientific Launches PCR Kits for Infectious Disease Detection in India

Thermo Fisher Scientific unveiled its latest line of PCR kits tailored for infectious disease detection, marking a significant development for diagnostics in India. These PCR kits are designed to enhance the speed and accuracy of infectious disease diagnosis, enabling healthcare professionals to make more informed decisions and improve patient outcomes.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Infectious Disease Diagnostic Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Infectious Disease Diagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Techne Corporation, bioMérieux SA, Cardinal Health Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., GE Healthcare, Grifols, S.A., Hologic Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Labsystems Diagnostics Oy, Merck KGaA, Olympus Corporation, Perkin Elmer, Inc., Pfizer Inc., Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Infectious Disease Diagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Instruments
Reagents
Software & Services
Technology
Biochemical Technology
Conventional Technology
Molecular Technology
Testing Type
Laboratory Testing
PoC Testing
Sample
Blood, Plasma, & Serum
Urine
Application
Bacterial Infection
Cardiovascular Infection
CNS Infection
Fungal Infection
Sexually Transmitted Disease
Viral Infection
End User
Diagnostic Laboratories
Hospital
Research Institutes
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year